Elite Pharmaceuticals, Inc. is a specialty pharmaceutical company that develops, manufactures, and distributes niche generic products. Elite’s product lines consist of immediate-release and controlled-release, solid oral dose products, which are marketed under the Elite Laboratories label, as well as pursuant to licenses granted to third-party pharmaceutical marketing and distribution organizations. Elite operates a cGMP and DEA registered facility for research, development, and manufacturing located in Northvale, NJ. For more information, visit www.elitepharma.com.
Company profile
Ticker
ELTP
Exchange
Website
CEO
Nasrat A. Hakim
Employees
Incorporated
Location
Fiscal year end
Industry (SIC)
Former names
ELITE PHARMACEUTICALS INC /DE/
SEC CIK
Corporate docs
IRS number
223542636
ELTP stock data
Latest filings (excl ownership)
S-8
Registration of securities for employees
28 Mar 24
S-8
Registration of securities for employees
28 Mar 24
8-K
Elite Pharmaceuticals, Inc. Reports Financial Results for Third Quarter of Fiscal Year 2024
14 Feb 24
10-Q
2024 Q3
Quarterly report
14 Feb 24
8-K
Regulation FD Disclosure
26 Dec 23
8-K
Elite Pharmaceuticals Announces First Product Shipment of Generic Adderall XR® to Marketing Partner Prasco, LLC
12 Dec 23
8-K
Results of Operations and Financial Condition
14 Nov 23
10-Q
2024 Q2
Quarterly report
14 Nov 23
8-K
Regulation FD Disclosure
25 Sep 23
8-K
Elite Pharmaceuticals, Inc. Appoints Carter Ward as Chief Financial Officer
7 Sep 23
Transcripts
ELTP
Earnings call transcript
2024 Q3
15 Feb 24
ELTP
Earnings call transcript
2024 Q2
15 Nov 23
ELTP
Earnings call transcript
2024 Q1
15 Aug 23
ELTP
Earnings call transcript
2023 Q4
30 Jun 23
ELTP
Earnings call transcript
2023 Q3
15 Feb 23
ELTP
Earnings call transcript
2023 Q2
15 Nov 22
ELTP
Earnings call transcript
2023 Q1
16 Aug 22
ELTP
Earnings call transcript
2022 Q4
30 Jun 22
ELTP
Earnings call transcript
2022 Q3
15 Feb 22
ELTP
Earnings call transcript
2022 Q2
16 Nov 21
Financial summary
Quarter (USD) | Sep 23 | Jun 23 | Mar 23 | Dec 22 | |
---|---|---|---|---|---|
Revenue | |||||
Cost of revenue | |||||
Operating income | |||||
Operating margin | |||||
Net income | |||||
Net profit margin | |||||
Cash on hand | |||||
Change in cash | |||||
Diluted EPS |
Annual (USD) | Mar 23 | Mar 22 | Mar 21 | Mar 20 | |
---|---|---|---|---|---|
Revenue | |||||
Cost of revenue | |||||
Operating income | |||||
Operating margin | |||||
Net income | |||||
Net profit margin | |||||
Cash on hand | |||||
Change in cash | |||||
Diluted EPS |
Cash burn rate (est.) | Burn method: Change in cash | Burn method: Operating income | Burn method: FCF (opex + capex) | Last Q | Avg 4Q | Last Q | Avg 4Q | Last Q | Avg 4Q |
---|---|---|---|---|---|---|
Cash on hand (at last report) | 9.08 mm | 9.08 mm | 9.08 mm | 9.08 mm | 9.08 mm | 9.08 mm |
Cash burn (monthly) | 138.48 k | 823.63 k | 910.93 k | (no burn) | 78.65 k | 45.41 k |
Cash used (since last report) | 923.80 k | 5.49 mm | 6.08 mm | n/a | 524.65 k | 302.95 k |
Cash remaining | 8.15 mm | 3.58 mm | 3.00 mm | n/a | 8.55 mm | 8.77 mm |
Runway (months of cash) | 58.9 | 4.3 | 3.3 | n/a | 108.7 | 193.2 |
Institutional ownership, Q3 2023
0.0% owned by funds/institutions
13F holders | Current |
---|---|
Total holders | 1 |
Opened positions | 1 |
Closed positions | 0 |
Increased positions | 0 |
Reduced positions | 0 |
13F shares | Current |
---|---|
Total value | 7.69 mm |
Total shares | 82.00 k |
Total puts | 0.00 |
Total calls | 0.00 |
Total put/call ratio | – |
Largest owners | Shares | Value |
---|---|---|
Fisher Asset Management | 82.00 k | $7.69 mm |
Recent insider trades
Date | Owner | Security | Transaction | Code | Indirect | 10b5-1 | $Price | #Shares | $Value | #Remaining |
---|---|---|---|---|---|---|---|---|---|---|
29 Mar 24 | Nasrat A Hakim | Common Stock | Grant | Acquire A | No | No | 0 | 49,534,368 | 0.00 | 216,649,250 |
29 Dec 23 | Nasrat A Hakim | Common Stock | Grant | Acquire A | Yes | No | 0.069 | 2,223,147 | 153.40 k | 2,223,147 |
22 Nov 23 | Barry H Dash | Common Stock | Grant | Acquire A | No | No | 0.0365 | 547,657 | 19.99 k | 3,235,555 |
22 Nov 23 | Davis S Caskey | Common Stock | Grant | Acquire A | No | No | 0.0365 | 547,657 | 19.99 k | 2,049,436 |
Press releases
Elite Pharmaceuticals, Inc. Reports Financial Results for Third Quarter of Fiscal Year 2024 ended December 31, 2023 and Provides Conference Call Information
14 Feb 24
Elite Pharmaceuticals, Inc. to Host Conference Call to Provide Corporate Update and Discuss Third Quarter 2024 Financial Results on February 15, 2024
8 Feb 24